BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Mansour-Ghanaei F, Pourmasoumi M, Hadi A, Joukar F. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Integr Med Res 2019;8:57-61. [PMID: 30949432 DOI: 10.1016/j.imr.2018.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
2 Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic Fatty Liver Disease and Obesity Treatment. Curr Obes Rep 2019;8:220-8. [PMID: 30945129 DOI: 10.1007/s13679-019-00345-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
3 Azizi N, Amini MR, Djafarian K, Shab-Bidar S. The Effects of Nigella sativa Supplementation on Liver Enzymes Levels: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Nutr Res 2021;10:72-82. [PMID: 33564654 DOI: 10.7762/cnr.2021.10.1.72] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Han EN, Cheong ES, Lee JI, Kim MC, Byrne CD, Sung KC. Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. Clin Hypertens 2015;21:22. [PMID: 26893932 DOI: 10.1186/s40885-015-0032-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mukai T, Egawa M, Takeuchi T, Yamashita H, Kusudo T. Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease. FEBS Open Bio. 2017;7:1009-1016. [PMID: 28680813 DOI: 10.1002/2211-5463.12240] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
6 Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2016;35:346-353. [PMID: 26156412 DOI: 10.1080/07315724.2015.1021057] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 7.7] [Reference Citation Analysis]
7 Tsuchiya S, Amano Y, Isono O, Imai M, Shimizu F, Asada M, Imai S, Harada A, Yasuhara Y, Tozawa R, Nagabukuro H. Pharmacological evaluation of pioglitazone and candesartan cilexetil in a novel mouse model of non-alcoholic steatohepatitis, modified choline-deficient, amino acid-defined diet fed low-density lipoprotein receptor knockout mice: Pharmacological validation of mouse model of NASH. Hepatol Res 2017;47:584-92. [DOI: 10.1111/hepr.12773] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Liu J, Jiang S, Zhao Y, Sun Q, Zhang J, Shen D, Wu J, Shen N, Fu X, Sun X, Yu D, Chen J, He J, Shi T, Ding Y, Fang L, Xue B, Li C. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions. J Pathol 2018;246:277-88. [PMID: 29971772 DOI: 10.1002/path.5131] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
9 Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2016;389:381-91. [PMID: 26753695 DOI: 10.1007/s00210-015-1207-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
10 Song Y, Zhou L, Jensen MD. Errors in measuring plasma free fatty acid concentrations with a popular enzymatic colorimetric kit. Clin Biochem 2019;66:83-90. [PMID: 30707886 DOI: 10.1016/j.clinbiochem.2019.01.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
12 Pardo V, González-Rodríguez Á, Guijas C, Balsinde J, Valverde ÁM. Opposite cross-talk by oleate and palmitate on insulin signaling in hepatocytes through macrophage activation. J Biol Chem 2015;290:11663-77. [PMID: 25792746 DOI: 10.1074/jbc.M115.649483] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
13 Hayder ZS, Kareem ZS. Resistin hormone in diabetic kidney disease and its relation to iron status and hepcidin. Int Urol Nephrol 2020;52:749-56. [PMID: 32173772 DOI: 10.1007/s11255-020-02434-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 DePaoli AM. 20 years of leptin: leptin in common obesity and associated disorders of metabolism. J Endocrinol 2014;223:T71-81. [PMID: 24973357 DOI: 10.1530/JOE-14-0258] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 7.1] [Reference Citation Analysis]
15 Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, Doosti M. Circulating Level of CTRP1 in Patients with Nonalcoholic Fatty Liver Disease (NAFLD): Is It through Insulin Resistance? PLoS One. 2015;10:e0118650. [PMID: 25767880 DOI: 10.1371/journal.pone.0118650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
16 Deminice R, de Castro GS, Brosnan ME, Brosnan JT. Creatine supplementation as a possible new therapeutic approach for fatty liver disease: early findings. Amino Acids 2016;48:1983-91. [PMID: 26832170 DOI: 10.1007/s00726-016-2183-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
17 Yuan X, Chen J, Cheng Q, Zhao Y, Zhang P, Shao X, Bi Y, Shi X, Ding Y, Sun X, Xue B. Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery. BMC Gastroenterol 2018;18:147. [PMID: 30285651 DOI: 10.1186/s12876-018-0871-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
18 Weta IW, Mahadewa TGB, Sutirtayasa WP, Subawa A, Sitanggang FP, Widyadharma IPE. The Comparison of Simple Anthropometric and Biochemical Parameters for Predicting Liver Steatosis in Obese Balinese Young Women. Open Access Maced J Med Sci 2018;6:2062-6. [PMID: 30559861 DOI: 10.3889/oamjms.2018.449] [Reference Citation Analysis]
19 Wang YG, Yang TL. Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. Exp Ther Med 2015;10:1777-83. [PMID: 26640549 DOI: 10.3892/etm.2015.2741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
20 Salter DM, Wei W, Nahar PP, Marques E, Slitt AL. Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin. Toxicol Sci 2021;182:82-95. [PMID: 33844015 DOI: 10.1093/toxsci/kfab043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Navekar R, Rafraf M, Ghaffari A, Asghari-jafarabadi M, Khoshbaten M. Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases. Journal of the American College of Nutrition 2017;36:261-7. [DOI: 10.1080/07315724.2016.1267597] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
22 Patel V, Joharapurkar A, Kshirsagar S, Patel M, Sutariya B, Patel H, Pandey D, Patel D, Ranvir R, Kadam S, Bahekar R, Jain M. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2018;96:587-596. [PMID: 29406832 DOI: 10.1139/cjpp-2017-0683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
23 Tang Q, Jiang S, Jia W, Shen D, Qiu Y, Zhao Y, Xue B, Li C. Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis. Eur J Pharmacol 2017;814:169-77. [PMID: 28843826 DOI: 10.1016/j.ejphar.2017.08.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
24 Oyarzún JE, Andia ME, Uribe S, Núñez Pizarro P, Núñez G, Montenegro G, Bridi R. Honeybee Pollen Extracts Reduce Oxidative Stress and Steatosis in Hepatic Cells. Molecules 2020;26:E6. [PMID: 33374984 DOI: 10.3390/molecules26010006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Gobejishvili L, Ghare S, Khan R, Cambon A, Barker DF, Barve S, McClain C, Hill D. Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease. Clin Immunol 2015;161:291-9. [PMID: 26408955 DOI: 10.1016/j.clim.2015.09.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
26 Hou B, Zhao Y, Qiang G, Yang X, Xu C, Chen X, Liu C, Wang X, Zhang L, Du G. Puerarin Mitigates Diabetic Hepatic Steatosis and Fibrosis by Inhibiting TGF-β Signaling Pathway Activation in Type 2 Diabetic Rats. Oxid Med Cell Longev 2018;2018:4545321. [PMID: 30057680 DOI: 10.1155/2018/4545321] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
27 Zhu S, Shi J, Ji C, Yang G, Xing J, Zhu F, Lin L, Xing A, Huang Z, Zhu C, Wei X, Zhang S, Gu J, Wu S. Association of the ideal cardiovascular behaviors and factors with the incidence of nonalcoholic fatty liver disease: a prospective study. European Journal of Gastroenterology & Hepatology 2018;30:578-82. [DOI: 10.1097/meg.0000000000001069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
28 Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Müller L, De Angelis M, Moreth K, Neff F, Perez-Tilve D, Fischer K, Lutter D, Sánchez-Garrido MA, Liu P, Tuckermann J, Malehmir M, Healy ME, Weber A, Heikenwalder M, Jastroch M, Kleinert M, Jall S, Brandt S, Flamant F, Schramm KW, Biebermann H, Döring Y, Weber C, Habegger KM, Keuper M, Gelfanov V, Liu F, Köhrle J, Rozman J, Fuchs H, Gailus-Durner V, Hrabě de Angelis M, Hofmann SM, Yang B, Tschöp MH, DiMarchi R, Müller TD. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell 2016;167:843-857.e14. [PMID: 27720451 DOI: 10.1016/j.cell.2016.09.014] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 20.2] [Reference Citation Analysis]
29 Moro K, Nagahashi M, Ramanathan R, Takabe K, Wakai T. Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer. World J Clin Cases 2016; 4(7): 155-164 [PMID: 27458590 DOI: 10.12998/wjcc.v4.i7.155] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
30 Ahsan F, Oliveri F, Goud HK, Mehkari Z, Mohammed L, Javed M, Althwanay A, Rutkofsky IH. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Cureus 2020;12:e10446. [PMID: 33072455 DOI: 10.7759/cureus.10446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Li J, Liu Z, Guo M, Xu K, Jiang M, Lu A, Gao X. Metabolomics profiling to investigate the pharmacologic mechanisms of berberine for the treatment of high-fat diet-induced nonalcoholic steatohepatitis. Evid Based Complement Alternat Med 2015;2015:897914. [PMID: 25977701 DOI: 10.1155/2015/897914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
32 Lee YS, Park JS, Lee DH, Lee DK, Kwon SW, Lee BW, Bae SH. The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition. Front Endocrinol (Lausanne) 2018;9:539. [PMID: 30298052 DOI: 10.3389/fendo.2018.00539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
33 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 167] [Article Influence: 27.0] [Reference Citation Analysis]
34 Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 2014;56:47-66. [PMID: 25083925 DOI: 10.1016/j.plipres.2014.07.002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 13.3] [Reference Citation Analysis]
35 López IC, Aroca FG, Bernal MDF, Mompeán JAL, Bernal ÁB, Martínez AMH, Barba EM, Velasco JAN, Paricio PP. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease. Obes Surg 2017;27:2347-53. [PMID: 28229316 DOI: 10.1007/s11695-017-2606-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
36 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Reference Citation Analysis]
37 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
38 Lewis JE, Atlas SE, Higuera OL, Fiallo A, Rasul A, Farooqi A, Kromo O, Lantigua LA, Tiozzo E, Woolger JM, Goldberg S, Mendez A, Rodriguez AE, Konefal J. The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:1751583. [PMID: 29853945 DOI: 10.1155/2018/1751583] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
39 Takahashi T, Sugawara W, Takiguchi Y, Takizawa K, Nakabayashi A, Nakamura M, Nagano-Ito M, Ichikawa S. Identification of Plants That Inhibit Lipid Droplet Formation in Liver Cells: Rubus suavissimus Leaf Extract Protects Mice from High-Fat Diet-Induced Fatty Liver by Directly Affecting Liver Cells. Evid Based Complement Alternat Med 2016;2016:4282758. [PMID: 27429636 DOI: 10.1155/2016/4282758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
40 Mahli A, Seitz T, Freese K, Frank J, Weiskirchen R, Abdel-Tawab M, Behnam D, Hellerbrand C. Therapeutic Application of Micellar Solubilized Xanthohumol in a Western-Type Diet-Induced Mouse Model of Obesity, Diabetes and Non-Alcoholic Fatty Liver Disease. Cells 2019;8:E359. [PMID: 30999670 DOI: 10.3390/cells8040359] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
41 Qian M, Lyu Q, Liu Y, Hu H, Wang S, Pan C, Duan X, Gao Y, Qi LW, Liu W, Wang L. Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice. Mar Drugs 2019;17:E391. [PMID: 31269758 DOI: 10.3390/md17070391] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
42 Cano A, Alonso C. Deciphering non-alcoholic fatty liver disease through metabolomics. Biochem Soc Trans 2014;42:1447-52. [PMID: 25233430 DOI: 10.1042/BST20140138] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
43 Abd El-Kader SM, El-Den Ashmawy EMS. Non-alcoholic fatty liver disease: The diagnosis and management. World J Hepatol 2015; 7(6): 846-858 [PMID: 25937862 DOI: 10.4254/wjh.v7.i6.846] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 27.7] [Reference Citation Analysis]
44 Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014;7:221-239. [PMID: 25045276 DOI: 10.2147/ceg.s62831] [Cited by in Crossref: 53] [Cited by in F6Publishing: 114] [Article Influence: 7.6] [Reference Citation Analysis]
45 Lubrano C, Valacchi G, Specchia P, Gnessi L, Rubanenko EP, Shuginina EA, Trukhanov AI, Korkina LG, De Luca C. Integrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome. Oxid Med Cell Longev 2015;2015:490613. [PMID: 26090072 DOI: 10.1155/2015/490613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
46 Salsamendi J, Pereira K, Kang K, Fan J. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report. J Radiol Case Rep 2015;9:36-43. [PMID: 26629307 DOI: 10.3941/jrcr.v9i9.2557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Zhou D, Pan Q, Liu XL, Yang RX, Chen YW, Liu C, Fan JG. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. J Gastroenterol Hepatol. 2017;32:1640-1648. [PMID: 28109017 DOI: 10.1111/jgh.13742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
48 Dong Y, Lu H, Li Q, Qi X, Li Y, Zhang Z, Chen J, Ren J. (5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. Life Sciences 2019;232:116644. [DOI: 10.1016/j.lfs.2019.116644] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
49 Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab 2014;25:538-45. [PMID: 25127738 DOI: 10.1016/j.tem.2014.07.001] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 16.4] [Reference Citation Analysis]
50 Schwenger KJ, Fischer SE, Jackson T, Okrainec A, Allard JP. In nonalcoholic fatty liver disease, Roux-en-Y gastric bypass improves liver histology while persistent disease is associated with lower improvements in waist circumference and glycemic control. Surgery for Obesity and Related Diseases 2018;14:1233-9. [DOI: 10.1016/j.soard.2018.06.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
51 Brandi G, De Lorenzo S, Di Girolamo S, Bellentani S, Saccoccio G, Biasco G. Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori 2015;101:e46-8. [DOI: 10.5301/tj.5000247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
53 Rinninella E, Mele MC, Merendino N, Cintoni M, Anselmi G, Caporossi A, Gasbarrini A, Minnella AM. The Role of Diet, Micronutrients and the Gut Microbiota in Age-Related Macular Degeneration: New Perspectives from the Gut⁻Retina Axis. Nutrients 2018;10:E1677. [PMID: 30400586 DOI: 10.3390/nu10111677] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
54 Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg 2015;25:2335-43. [PMID: 25920616 DOI: 10.1007/s11695-015-1696-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
55 Jamialahmadi T, Nematy M, Jangjoo A, Goshayeshi L, Abdalla MA, Akhlaghi S, Sathyapalan T, Sahebkar A. The predictive role of parathyroid hormone for non-alcoholic fatty liver disease based on invasive and non-invasive findings in candidates of bariatric surgery. Eat Weight Disord 2021. [PMID: 33999371 DOI: 10.1007/s40519-021-01151-2] [Reference Citation Analysis]
56 Aigner E, Feldman A, Datz C. Obesity as an emerging risk factor for iron deficiency. Nutrients 2014;6:3587-600. [PMID: 25215659 DOI: 10.3390/nu6093587] [Cited by in Crossref: 138] [Cited by in F6Publishing: 120] [Article Influence: 19.7] [Reference Citation Analysis]
57 Hossain MM, Mukheem A, Kamarul T. The prevention and treatment of hypoadiponectinemia-associated human diseases by up-regulation of plasma adiponectin. Life Sciences 2015;135:55-67. [DOI: 10.1016/j.lfs.2015.03.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
58 Rashidmayvan M, Mohammadshahi M, Seyedian SS, Haghighizadeh MH. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. J Diabetes Metab Disord 2019;18:453-9. [PMID: 31890671 DOI: 10.1007/s40200-019-00439-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
59 Smits LP, Coolen BF, Panno MD, Runge JH, Nijhof WH, Verheij J, Nieuwdorp M, Stoker J, Beuers UH, Nederveen AJ, Stroes ES. Noninvasive Differentiation between Hepatic Steatosis and Steatohepatitis with MR Imaging Enhanced with USPIOs in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. Radiology 2016;278:782-91. [DOI: 10.1148/radiol.2015150952] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
60 Chaney A. Treating the patient with nonalcoholic fatty liver disease. Nurse Pract 2015;40:36-42; quiz 42-3. [PMID: 26474202 DOI: 10.1097/01.NPR.0000472248.28703.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
61 Jurgoński A, Fotschki B, Juśkiewicz J. Disparate metabolic effects of blackcurrant seed oil in rats fed a basal and obesogenic diet. Eur J Nutr 2015;54:991-9. [PMID: 25311060 DOI: 10.1007/s00394-014-0775-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
62 Bjørklund G, Peana M, Pivina L, Dosa A, Aaseth J, Semenova Y, Chirumbolo S, Medici S, Dadar M, Costea DO. Iron Deficiency in Obesity and after Bariatric Surgery. Biomolecules 2021;11:613. [PMID: 33918997 DOI: 10.3390/biom11050613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Torrinhas RS, Waitzberg DL. A Double-blinded Randomized Placebo-controlled Clinical Trial of Omega-3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2016;50:180. [PMID: 26448136 DOI: 10.1097/MCG.0000000000000412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Rahmadi M, Nurhan AD, Pratiwi ED, Prameswari DA, Panggono SM, Nisak K, Khotib J. The effect of various high-fat diet on liver histology in the development of NAFLD models in mice. J Basic Clin Physiol Pharmacol 2021;32:547-53. [PMID: 34214382 DOI: 10.1515/jbcpp-2020-0426] [Reference Citation Analysis]
65 Hendy OM, Elsabaawy MM, Aref MM, Khalaf FM, Oda AMA, El Shazly HM. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS 2017;125:607-13. [DOI: 10.1111/apm.12696] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
66 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
67 Vander Naalt SJ, Gurria JP, Holterman AL. Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med 2014;6:103-12. [PMID: 25378958 DOI: 10.2147/HMER.S64819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
68 Garjani A, Safaeiyan A, Khoshbaten M. Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon 2015;15:e24449. [PMID: 25741373 DOI: 10.5812/hepatmon.24449] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
69 Pervez MA, Khan DA, Ijaz A, Khan S. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease. Turk J Gastroenterol 2018;29:170-6. [PMID: 29749323 DOI: 10.5152/tjg.2018.17297] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
70 Dong S, Zhan ZY, Cao HY, Wu C, Bian YQ, Li JY, Cheng GH, Liu P, Sun MY. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease. World J Gastroenterol 2017; 23(15): 2771-2784 [PMID: 28487615 DOI: 10.3748/wjg.v23.i15.2771] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
71 Cheng J, Zhou ZW, Sheng HP, He LJ, Fan XW, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, Cao C, Zhou SF. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther 2015;9:33-78. [PMID: 25552899 DOI: 10.2147/DDDT.S72892] [Cited by in Crossref: 27] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
72 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol 2015; 7(3): 575-582 [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
73 Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, Deschenes M, Ghali P. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. PLoS One. 2015;10:e0128774. [PMID: 26083565 DOI: 10.1371/journal.pone.0128774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]